Phase 2CompletedAge-related condition
A Dose Titration Study of CPC-201 in Patients With Dementia of Alzheimer's Type (CPC-12)
A Phase II, Dose Titration Study of CPC-201 in Patients With Dementia of Alzheimer's Type
- Sponsor
- Chase Pharmaceuticals Corporation, an affiliate of Allergan plc (Industry)
- Enrolment
- 28 enrolled
- Conditions
- Dementia of Alzheimer's Type
- Interventions
- Donepezil; Solifenacin
- Ages
- adults, older adults
- Registry
- NCT02549196
Full record on ClinicalTrials.gov
From the registry
This is a Phase II, ascending dose study of CPC-201 in patients with dementia of Alzheimer's type to determine the optimal dose titration schedule.
Primary outcomes
- Number of Participants Who Reached the Maximum Allowed Dose (MAD) in Their Respective Cohort
History
Results first posted
Last registry update
Primary completion
Started
Registered